Editorial
Cholesterol pathway the Achilles heel in prostate cancer metastasis
Translational Andrology and Urology
2018;
7
(Suppl 6)
:S686-S687
.
(20 December 2018)
Nutritional implications for quality of life in bladder cancer survivors
Translational Andrology and Urology
2018;
7
(Suppl 6)
:S688-S691
.
(20 December 2018)
T1G3 bladder cancer, bacillus Calmette-Guerin and radical cystectomy: continued debate
Translational Andrology and Urology
2018;
7
(Suppl 6)
:S692-S695
.
(20 December 2018)
Will long term oncologic follow-up make the case for robotic assisted radical cystectomy?
Translational Andrology and Urology
2018;
7
(Suppl 6)
:S696-S698
.
(20 December 2018)
Treating bladder adenocarcinoma
Translational Andrology and Urology
2018;
7
(Suppl 6)
:S699-S701
.
(20 December 2018)
The association of BMI with risk of recurrence and progression in patients with non-muscle-invasive bladder cancer
Translational Andrology and Urology
2018;
7
(Suppl 6)
:S702-S705
.
(20 December 2018)
An immediate intravesical instillation of mitomycin C is of benefit in all prognostic risk groups with non-muscle-invasive bladder cancers
Translational Andrology and Urology
2018;
7
(Suppl 6)
:S706-S709
.
(20 December 2018)
Does obesity impact bladder cancer prognosis?—a long-lasting debate
Translational Andrology and Urology
2018;
7
(Suppl 6)
:S710-S711
.
(20 December 2018)
A retrosigmoid ileal conduit might prevent ureteroileal anastomotic stricture after ileal conduit diversion
Translational Andrology and Urology
2018;
7
(Suppl 6)
:S712-S714
.
(20 December 2018)
Targeting splicing factors as molecular non-muscle invasive bladder cancer predictors
Translational Andrology and Urology
2018;
7
(Suppl 6)
:S715-S717
.
(20 December 2018)
Immunonutrition in radical cystectomy: a novel approach to reduce postoperative complications?
Translational Andrology and Urology
2018;
7
(Suppl 6)
:S718-S719
.
(20 December 2018)
Do we have all the facts to determine the impact of bacillus Calmette-Guérin therapy on bladder cancer?
Translational Andrology and Urology
2018;
7
(Suppl 6)
:S720-S722
.
(20 December 2018)
Editorial comment: bladder preservation as a treatment strategy in muscle-invasive bladder cancer
Translational Andrology and Urology
2018;
7
(Suppl 6)
:S723-S726
.
(20 December 2018)
The patient’s perspective on blue light flexible cystoscopy: insight from a prospective clinical study
Translational Andrology and Urology
2018;
7
(Suppl 6)
:S727-S728
.
(20 December 2018)
Redefining the role of immediate intravesical instillation of mitomycin C in non-muscle invasive bladder cancer
Translational Andrology and Urology
2018;
7
(Suppl 6)
:S729-S731
.
(20 December 2018)
Sarcopenia is a reliable predictor of outcomes following radical cystectomy for bladder cancer
Translational Andrology and Urology
2018;
7
(Suppl 6)
:S732-S734
.
(20 December 2018)
Is experience with extracorporeal urinary diversion following robotic assisted radical cystectomy necessary before transitioning to intracorporeal urinary diversion?
Translational Andrology and Urology
2018;
7
(Suppl 6)
:S735-S737
.
(20 December 2018)
High economic burden of immunotherapy underlines the need of predictive biomarkers for the individual therapy algorithm in metastatic bladder cancer
Translational Andrology and Urology
2018;
7
(Suppl 6)
:S738-S740
.
(20 December 2018)
Is it oncologically and clinically safe to adopt a bladder sparing approach in complete responders following neoadjuvant chemotherapy alone without proceeding to a radical cystectomy?
Translational Andrology and Urology
2018;
7
(Suppl 6)
:S741-S743
.
(20 December 2018)
Does robotic radical cystectomy impede oncological outcome in bladder cancer patients?
Translational Andrology and Urology
2018;
7
(Suppl 6)
:S744-S746
.
(20 December 2018)
Decreasing incidence of venous thromboembolic events after radical cystectomy: are we finally improving?
Translational Andrology and Urology
2018;
7
(Suppl 6)
:S747-S750
.
(20 December 2018)
Is adjuvant chemotherapy better than neoadjuvant chemotherapy for those with node positive disease?
Translational Andrology and Urology
2018;
7
(Suppl 6)
:S751-S752
.
(20 December 2018)
Biomarkers for the prediction of oncologic outcomes in nonmuscle invasive bladder cancer: state of affairs and new frontiers
Translational Andrology and Urology
2018;
7
(Suppl 6)
:S753-S755
.
(20 December 2018)
Challenging the dogma of simultaneous resection of bladder tumor and benign prostate
Translational Andrology and Urology
2018;
7
(Suppl 6)
:S756-S757
.
(20 December 2018)
The timing of radical cystectomy following neoadjuvant chemotherapy
Translational Andrology and Urology
2018;
7
(Suppl 6)
:S758-S759
.
(20 December 2018)
Impact of immunonutrition on radical cystectomy immunoresponse and outcomes; opportunity for peri-operative optimization
Translational Andrology and Urology
2018;
7
(Suppl 6)
:S760-S762
.
(20 December 2018)
Frailty and sarcopenia impact surgical and oncologic outcomes after radical cystectomy in patients with bladder cancer
Translational Andrology and Urology
2018;
7
(Suppl 6)
:S763-S764
.
(20 December 2018)
Letter to the Editor
The emerging role of PTBP1 in human cancer: novel prognostic factor in non-muscle invasive bladder cancer
Translational Andrology and Urology
2018;
7
(Suppl 6)
:S765-S767
.
(20 December 2018)
Response to editorial comment “A retrosigmoid ileal conduit might prevent ureteroileal anastomotic stricture after ileal conduit diversion”
Translational Andrology and Urology
2018;
7
(Suppl 6)
:S768-S769
.
(20 December 2018)
News
Translational Andrology and Urology is indexed in SCIE: a milestone for the development of TAU
Translational Andrology and Urology
2018;
7
(Suppl 6)
:S770-S775
.
(20 December 2018)
Disclosure:
The supplement was published without any sponsorship or funding.
